KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Capital Expenditures (2016 - 2025)

Opko Health (OPK) has disclosed Capital Expenditures for 16 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 50.75% year-over-year to $2.7 million, compared with a TTM value of $12.3 million through Dec 2025, down 50.91%, and an annual FY2025 reading of $12.3 million, down 50.91% over the prior year.
  • Capital Expenditures was $2.7 million for Q4 2025 at Opko Health, down from $3.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $9.2 million in Q1 2021 and bottomed at $2.7 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $5.5 million, with a median of $5.4 million recorded in 2022.
  • The sharpest move saw Capital Expenditures skyrocketed 88.84% in 2024, then crashed 60.5% in 2025.
  • Year by year, Capital Expenditures stood at $6.7 million in 2021, then decreased by 5.85% to $6.3 million in 2022, then tumbled by 52.3% to $3.0 million in 2023, then soared by 79.12% to $5.4 million in 2024, then tumbled by 50.75% to $2.7 million in 2025.
  • Business Quant data shows Capital Expenditures for OPK at $2.7 million in Q4 2025, $3.1 million in Q3 2025, and $3.3 million in Q2 2025.